益生菌|改变皮肤微生态:益生菌在皮肤病中的应用( 八 )


46 Yu Y, Champer J, Garban H et al. Typing of Propionibacterium acnes: a review of methods and comparative analysis. Br J Dermatol 2015; 172:1204–9.
47 McDowell A, Nagy I, Magyari M et al. The opportunistic pathogen Propionibacterium acnes: insights into typing, human disease, clonal diversification and CAMP factor evolution. PLOS ONE 2013; 8: e70897.
48 Scholz CF, Jensen A, Lomholt HB et al. A novel high-resolution single locus sequence typing scheme for mixed populations of Propionibacterium acnes in vivo. PLOS ONE 2014; 9:e104199.
49 Fitz-Gibbon S, Tomida S, Chiu BH et al. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J Invest Dermatol 2013; 133:2152–60.
50 Tomida S, Nguyen L, Chiu BH et al. Pan-genome and comparative genome analyses of Propionibacterium acnes reveal its genomic diversity in the healthy and diseased human skin microbiome. MBio 2013; 4:e00003–13.
51 Yu Y, Champer J, Agak GW et al. Different Propionibacterium acnes phylotypes induce distinct immune responses and express unique surface and secreted proteomes. J Invest Dermatol 2016; 136:2221–8.
52 Kober MM, Bowe WP. The effect of probiotics on immune regulation, acne, and photoaging. Int J Womens Dermatol 2015; 1:85–9.
53 Kang BS, Seo JG, Lee GS et al. Antimicrobial activity of enterocins from Enterococcus faecalis SL-5 against Propionibacterium acnes, the causative agent in acne vulgaris, and its therapeutic effect. J Microbiol 2009; 47:101–9.
54 AOBiome Therapeutics. AOBiome Therapeutics reports positive efficacy results from phase 2b clinical trial of ammonia oxidizing bacteria (AOB) for the treatment of acne vulgaris. Available at: https://www.aobiome.com/pressreleases/aobiome-therapeuticsreports-positive-efficacy-results-from-phase-2b-clinical-trial-of-ammonia-oxidizing-bacteria-aob-for-the-treatment-of-acne-vulgaris (last accessed 12 June 2019).
55 Nodake Y, Matsumoto S, Miura R et al. Pilot study on novel skin care method by augmentation with Staphylococcus epidermidis, an autologous skin microbe – a blinded randomized clinical trial. J Dermatol Sci 2015; 79:119–26.
56 Wang Y, Kuo S, Shu M et al. Staphylococcus epidermidis in the human skin microbiome mediates fermentation to inhibit the growth of Propionibacterium acnes: implications of probiotics in acne vulgaris. Appl Microbiol Biotechnol 2014; 98:411–24.
57 Liu J, Yan R, Zhong Q et al. The diversity and host interactions of Propionibacterium acnes bacteriophages on human skin. ISME J 2015; 9:2078–93.
58 Marinelli LJ, Fitz-Gibbon S, Hayes C et al. Propionibacterium acnes bacteriophages display limited genetic diversity and broad killing activity against bacterial skin isolates. MBio 2012; 3:e00279–12.
59 Brown TL, Petrovski S, Dyson ZA et al. The formulation of bacteriophage in a semi solid preparation for control of Propionibacterium acnes growth. PLOS ONE 2016; 11:e0151184.
60 Jonczyk-Matysiak E, Weber-Dabrowska B, Zaczek M et al. Prospects of phage application in the treatment of acne caused by Propionibacterium acnes. Front Microbiol 2017; 8:164.
61 Fry L, Baker BS, Powles AV et al. Is chronic plaque psoriasis triggered by microbiota in the skin? Br J Dermatol 2013; 169:47–52.
62 Martin DA, Towne JE, Kricorian G et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 2013; 133:17–26.
63 Alekseyenko AV, Perez-Perez GI, De Souza A et al. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome 2013; 1:31.
64 Fahlen A, Engstrand L, Baker BS et al. Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol Res 2012; 304:15–22.
65 Gao Z, Tseng CH, Strober BE et al. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLOS ONE 2008; 3: e2719.
66 Chen YH, Wu CS, Chao YH et al. Lactobacillus pentosus GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-like mice. J Food Drug Anal 2017; 25:559–66.

推荐阅读